A new treatment for kidney cancer patients may have been a discovery made by researchers at the Dana-Farber Cancer Institute in conjunction with Harvard Medical School.
According to the New England Journal of Medicine , where these two studies were published separately, a combination of medications may be more effective than conventional drugs used to treat cancer.
Despite being positive, the drugs are still in the testing phase and, when completed, still need to be approved by the Federal Agency of the United States Department of Health and Human Services (FDA). This can cause the composition to take longer to become available.
The researchers saw that the combined drugs were able to reduce the tumors of the patient with kidney cancer already in terminal stages, increasing their life span.
In addition, the ability to block the growth of the tumor, preventing some of its molecules from spreading in the body, was greater when compared to other drugs indicated for the treatment of kidney cancer.
What does the first study say?
The first test carried out was with the combination of avelumab + axitinib , against the traditional treatment since 2007, sunitinib .
For this, the scientists brought together a total of 886 patients and divided them into two groups: those who would be treated with the new drugs and those who would take the conventional medicine. And, from there, they started to monitor the effects.